This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05327/identifier/bindingdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05327/identifier/pubchem-compound/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB05327/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/drugbank/drug/DB05327/identifier/chemspider/

Statements

Subject Item
n2:DB05327
rdf:type
n5:Drug
n5:description
AS-3201 is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels.
n5:generalReferences
# Bril V, Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006 Jan;29(1):68-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16373898
n5:group
investigational
n5:indication
Investigated for use/treatment in neuropathy (diabetic).
owl:sameAs
n11:DB05327
dcterms:title
AS-3201
adms:identifier
n4:135685 n7:DB05327 n8:153948 n12:50067407
n5:mechanismOfAction
AS-3201 alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This drug has a stronger inhibitory effect and is longer acting compared to other drugs in this therapeutic area. AS-3201 showed good penetration into the nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose in a clinical study.
n5:IUPAC-Name
n6:271B4123-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4129-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4128-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4125-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4126-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4127-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4121-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B411F-363D-11E5-9242-09173F13E4C5 n6:271B4122-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4120-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B412F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4130-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B412A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B412B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B412D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B412C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B412E-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4135-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4137-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4138-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4134-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4133-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4136-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4124-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4131-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4132-363D-11E5-9242-09173F13E4C5